Interleukin-27 gene delivery for modifying malignant interactions between prostate tumor and bone

Human Gene Therapy

Volumn 24, Issue 12, 2013, Pages 970-981

  Zolochevska, Olga ^a   Ellis, Jayne ^a   Parelkar, Sangram ^b   Chan Seng, Delphine ^b   Emrick, Todd ^b   Wei, Jingna ^c   Patrikeev, Igor ^c   Motamedi, Massoud ^c   Figueiredo, Marxa L ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 27;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOACCUMULATION; BONE CANCER; BONE METASTASIS; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; EFFECTOR CELL; GENE EXPRESSION; GENE TARGETING; IMMUNOCOMPETENCE; IN VIVO GENE TRANSFER; IN VIVO STUDY; LENTIVIRINAE; MALE; MOUSE; NONHUMAN; OSTEOBLAST; OSTEOCLAST; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; VIRAL GENE DELIVERY SYSTEM;

BONE NEOPLASMS; CELL DIFFERENTIATION; GENE TRANSFER TECHNIQUES; HUMANS; INTERLEUKIN-27; MALE; OSTEOBLASTS; OSTEOCLASTS; PROSTATIC NEOPLASMS;

EID: 84890501693     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.091     Document Type: Article

References (58)

1. Berruti, A., Dogliotti, L., Bitossi, R., et al. (2000). Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline. J. Urol. 164, 1248-1253.
2. Berruti, A., Dogliotti, L., Tucci, M., et al. (2001). Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates. J. Urol. 166, 2023-2031. (Pubitemid 33065209)
3. Boyce, B.F., Yoneda, T., and Guise, T.A. (1999). Factors regulating the growth of metastatic cancer in bone. Endocr. Relat. Cancer 6, 333-347. (Pubitemid 29459783)
4. Bubendorf, L., Schopfer, A., Wagner, U., et al. (2000). Metastatic patterns of prostate cancer: an autopsy study of 1, 589 patients. Hum. Pathol. 31, 578-583. (Pubitemid 30323983)
5. Campbell, G.M., Ominsky, M.S., and Boyd, S.K. (2011). Bone quality is partially recovered after the discontinuation of RANKL administration in rats by increased bone mass on existing trabeculae: an in vivo micro-CT study. Osteoporos. Int. 22, 931-942.
6. Carlin, B.I., and Andriole, G.L. (2000). The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 88, 2989-2994. (Pubitemid 30413181)
7. Clark, P.E., and Torti, F.M. (2003). Prostate cancer and bone metastases: medical treatment. Clin. Orthop. Relat. Res. S148-S157. (Pubitemid 37323332)
8. Cocco, C., Giuliani, N., Di Carlo, E., et al. (2010). Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin. Cancer Res. 16, 4188-4197.
9. Coleman, R.E. (1997). Skeletal complications of malignancy. Cancer 80, 1588-1594. (Pubitemid 27444031)
10. Coleman, R.E. (2001). Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 27, 165-176. (Pubitemid 32452017)
11. Corti, A., Pastorino, F., Curnis, F., et al. (2011). Targeted drug delivery and penetration into solid tumors. Med. Res. Rev. 32, 1078-1091.
12. Daniell, H.W. (1997). Osteoporosis after orchiectomy for prostate cancer. J. Urol. 157, 439-444. (Pubitemid 27026812)
13. Dieli, F., Vermijlen, D., Fulfaro, F., et al. (2007). Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450-7457. (Pubitemid 47206575)
14. Dieli, F., Caccamo, N., and Meraviglia, S. (2008). Advances in immunotherapy of castration-resistant prostate cancer: bisphosphonates, phosphoantigens and more. Curr. Opin. Investig. Drugs 9, 1089-1094.
15. Engel, M.A., and Neurath, M.F. (2010). Anticancer properties of the IL-12 family-focus on colorectal cancer. Curr. Med. Chem. 17, 3303-3308.
16. Feng, X.M., Chen, X.L., Liu, N., et al. (2007). Interleukin-27 upregulates major histocompatibility complex class II expression in primary human endothelial cells through induction of major histocompatibility complex class II transactivator. Hum. Immunol. 68, 965-972.
17. Figueiredo, M.L., Dayan, S., Kim, Y., et al. (2006). Expression of cell-cycle regulator CDK2-associating protein 1 (p12CDK2AP1) in transgenic mice induces testicular and ovarian atrophy in vivo. Mol. Reprod. Dev. 73, 987-997. (Pubitemid 43993537)
18. Figueiredo, M.L., Kao, C., and WU, L. (2007). Advances in preclinical investigation of prostate cancer gene therapy. Mol. Ther. 15, 1053-1064. (Pubitemid 46813607)
19. Freeman, T.A., Patel, P., Parvizi, J., et al. (2009). Micro-CT analysis with multiple thresholds allows detection of bone formation and resorption during ultrasound-treated fracture healing. J. Orthop. Res. 27, 673-679.
20. Furukawa, M., Takaishi, H., Takito, J., et al. (2009). IL-27 abrogates receptor activator of NF-kappa B ligand-mediated osteoclastogenesis of human granulocyte-macrophage colonyforming unit cells through STAT1-dependent inhibition of c-Fos. J. Immunol. 183, 2397-2406.
21. Goltzman, D. (1997). Mechanisms of the development of osteoblastic metastases. Cancer 80, 1581-1587. (Pubitemid 27444030)
22. Hatano, T., Oishi, Y., Furuta, A., et al. (2000). Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer. BJU Int. 86, 449-452.
23. Hisada, M., Kamiya, S., Fujita, K., et al. (2004). Potent antitumor activity of interleukin-27. Cancer Res. 64, 1152-1156. (Pubitemid 38176923)
24. Hsu, H., Lacey, D.L., Dunstan, C.R., et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96, 3540-3545. (Pubitemid 29168945)
25. Hung, T.T., Chan, J., Russell, P.J., and Power, C.A. (2011). Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One 6, e19389.
26. Iranikhah, M., Wilborn, T.W., Wensel, T.M., and Ferrell, J.B. (2012). Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor. Pharmacotherapy 32, 274-284.
27. Johnson, L.C., Johnson, R.W., Munoz, S.A., et al. (2011). Longitudinal live animal micro-CT allows for quantitative analysis of tumor-induced bone destruction. Bone 48, 141-151.
28. Kalliolias, G.D., Zhao, B., Triantafyllopoulou, A., et al. (2010). Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum. 62, 402-413.
29. Kamiya, S., Nakamura, C., Fukawa, T., et al. (2007). Effects of IL-23 and IL-27 on osteoblasts and osteoclasts: inhibitory effects on osteoclast differentiation. J. Bone Miner. Metab. 25, 277-285. (Pubitemid 47283267)
30. Lucas, S., Ghilardi, N., Li, J., and De Sauvage, F.J. (2003). IL-27 regulates IL-12 responsiveness of naive CD4 + T cells through Stat1-dependent and-independent mechanisms. Proc. Natl. Acad. Sci. USA 100, 15047-15052. (Pubitemid 37518014)
31. Mani, R.S., Iyer, M.K., Cao, Q., et al. (2012). TMPRSS2-ERGmediated feed-forward regulation of wild-type ERG in human prostate cancers. Cancer Res. 71, 5387-5392.
32. McCabe, N.P., Madajka, M., Vasanji, A., and Byzova, T.V. (2008). Intraosseous injection of RM1 murine prostate cancer cells promotes rapid osteolysis and periosteal bone deposition. Clin. Exp. Metastasis 25, 581-590.
33. Miyazaki, H., Nishimatsu, H., Kume, H., et al. (2012). Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel. BJU Int. 110, E520-E525.
34. Morandi, F., Prigione, I., and Airoldi, I. (2012). Human TCRgammadelta + T cells represent a novel target for IL-27 activity. Eur. J. Immunol. 42, 1547-1552.
35. Morgan, E.F., Mason, Z.D., Chien, K.B., et al. (2009). Microcomputed tomography assessment of fracture healing: relationships among callus structure, composition, and mechanical function. Bone 44, 335-344.
36. Mundy, G.R. (2002). Metastasis to bone: causes, consequences and therapeutic opportunities. Nat. Rev. Cancer 2, 584-593. (Pubitemid 37328925)
37. Mundy, G.R., and Guise, T.A. (1997). Hypercalcemia of malignancy. Am. J. Med. 103, 134-145. (Pubitemid 27352118)
38. Nelson, P.L., Zolochevska, O., Figueiredo, M.L., et al. (2011). Regulation of Ca(2 + )-entry in pancreatic alpha-cell line by transient receptor potential melastatin 4 plays a vital role in glucagon release. Mol. Cell Endocrinol. 335, 126-134.
39. Osborn, J.L., Getzenberg, R.H., and Trump, D.L. (1995). Spinal cord compression in prostate cancer. J. Neurooncol. 23, 135-147.
40. Parelkar, S.S., Chan-Seng, D., and Emrick, T. (2011). Reconfiguring polylysine architectures for controlling polyplex binding and non-viral transfection. Biomaterials 32, 2432-2444.
41. Roodman, G.D. (2004). Mechanisms of bone metastasis. N. Engl. J. Med. 350, 1655-1664.
42. Roudier, M.P., Corey, E., True, L.D., et al. (2004). Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat. Res. 118, 311-339.
43. Roudier, M.P., Morrissey, C., True, L.D., et al. (2008). Histopathological assessment of prostate cancer bone osteoblastic metastases. J. Urol. 180, 1154-1160.
44. Saad, F. (2002). Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone. Clin. Prostate Cancer 1, 145-152. (Pubitemid 37012395)
45. Saad, F., Gleason, D.M., Murray, R., et al. (2004). Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J. Natl. Cancer Inst. 96, 879-882. (Pubitemid 38807610)
46. Salcedo, R., Stauffer, J.K., Lincoln, E., et al. (2004). IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8 + T cells. J. Immunol. 173, 7170-7182. (Pubitemid 39628152)
47. Salcedo, R., Hixon, J.A., Stauffer, J.K., et al. (2009). Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J. Immunol. 182, 4328-4338.
48. Sameni, M., Dosescu, J., Yamada, K.M., et al. (2008). Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol. Imaging 7, 199-213.
49. Smith, M.R. (2007). Androgen deprivation therapy for prostate cancer: new concepts and concerns. Curr. Opin. Endocrinol. Diabetes Obes. 14, 247-254. (Pubitemid 46684481)
50. Takeda, A., Hamano, S., Yamanaka, A., et al. (2003). Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170, 4886-4890. (Pubitemid 36554716)
51. Wong, M.H., Stockler, M.R., and Pavlakis, N. (2012). Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst. Rev. 2, CD003474.
52. Yoshimoto, T., Morishima, N., Mizoguchi, I., et al. (2008). Antiproliferative activity of IL-27 on melanoma. J. Immunol. 180, 6527-6535.
53. Zhu, S., Lee, D.A., and Li, S. (2010). IL-12 and IL-27 sequential gene therapy via intramuscular electroporation delivery for eliminating distal aggressive tumors. J. Immunol. 184, 2348-2354.
54. Zolochevska, O., and Figueiredo, M.L. (2009). Expression of cell cycle regulator cdk2ap1 suppresses tumor cell phenotype by non-cell-autonomous mechanisms. Oral Oncol. 45, e106-e112.
55. Zolochevska, O., and Figueiredo, M.L. (2011). Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells. Prostate 71, 353-367.
56. Zolochevska, O., and Figueiredo, M.L. (2012). Sonoporationbased strategies for cancer therapy. Front. Biosci. (Schol. Ed.) 4, 988-1006.
57. Zolochevska, O., Xia, X., Williams, B.J., et al. (2011). Sonoporation delivery of interleukin-27 gene therapy efficiently reduces prostate tumor cell growth in vivo. Hum. Gene Ther. 22, 1537-1550.
58. Zolochevska, O., Ellis, J., and Figueiredo, M.L. (2013). Interleukin-27 expression modifies prostate cancer cell crosstalk with bone and immune cells. J. Cell Physiol. 228, 1127-1136.